EDITORIALS
- From bench to patient: model systems in drug discovery
Drug Discovery Collection: This Editorial introduces the new DMM Special Collection entitled ‘From bench to patient: model systems in drug discovery’, providing a summary of its contents and highlighting the impact of multiple model systems in moving new discoveries from bench to patient.
- Improving translational studies: lessons from rare neuromuscular diseases
Drug Discovery Collection: This Editorial reviews problems and some solutions to the translational use of animal models in the rare neuromuscular diseases context. This can serve as a model for other disease fields.
A MODEL FOR LIFE
REVIEW
- GEMMs as preclinical models for testing pancreatic cancer therapies
Drug Discovery Collection: This Review discusses GEMMs of human pancreatic cancer, particularly focusing on the KPC model, its use in preclinical research, advantages and disadvantages, and its potential for predicting clinical outcomes.
RESEARCH ARTICLES
- A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics
Editor's choice - Drug Discovery Collection: The study describes a rapid in vivo screen for novel strategies to treat pancreatic ductal adenocarcinoma (PDA).
- Treatment with a novel oleic-acid–dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats
Drug Discovery Collection: OLHHA is a safe drug with hepatoprotective and anti-steatotic effects on non-alcoholic fatty liver disease in obese rats.
- Precision-cut kidney slices (PCKS) to study development of renal fibrosis and efficacy of drug targeting ex vivo
Drug Discovery Collection: TGFβ induces renal fibrosis in ex vivo cultured precision-cut kidney slices, which can be attenuated by IFNγ.
- A calixpyrrole derivative acts as an antagonist to GPER, a G-protein coupled receptor: mechanisms and models
Drug Discovery Collection: This paper highlights mechanisms through which a calixpyrrole derivative acts as a newly identified selective antagonist of GPER in different model systems.
- Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice
Drug Discovery Collection: Neuroblastomas are sensitive to treatment with the glycolytic inhibitor 2-deoxyglucose, which can simultaneously target cancer and endothelial cells to suppress tumor growth.
RESOURCE ARTICLE
- From drug response profiling to target addiction scoring in cancer cell models
Drug Discovery Collection: The authors take a pan-cancer approach that provides functional insights into molecular vulnerabilities across various cancer subtypes and patient-specific target addiction patterns that could lead to actionable treatment strategies.
RESEARCH ARTICLES
- Impaired APP activity and altered Tau splicing in embryonic stem cell-derived astrocytes obtained from an APPsw transgenic minipig
Summary: Insight into astrocyte and radial glia pathology in an in vitro culture system derived from the APPsw pig.
- Interplay among Drosophila transcription factors Ets21c, Fos and Ftz-F1 drives JNK-mediated tumor malignancy
Summary: This study provides genetic evidence that malignancy driven by oncogenic Ras and loss of polarity requires transcription factors of three distinct protein families, acting in synergy downstream of JNK signaling.
- OTX2 exhibits cell-context-dependent effects on cellular and molecular properties of human embryonic neural precursors and medulloblastoma cells
Summary: Human embryonic stem cell neural derivatives can be used to model the molecular and cellular properties of medulloblastoma.
- Albumin stimulates renal tubular inflammation through an HSP70-TLR4 axis in mice with early diabetic nephropathy
Summary: Activation of the HSP70-TLR4 axis by albumin in the tubular cell induces tubular inflammation and injury.
- Transient alteration of the vestibular calyceal junction and synapse in response to chronic ototoxic insult in rats
Summary: New forms of damage and repair have been identified in the vestibular sensory epithelium using a rat model of chronic ototoxicity and recovery that causes reversible vestibular dysfunction.
This issue
JUMP TO
Other journals from The Company of Biologists
DMM and COVID-19
We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.
Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.
Travel grants and how to use them (when there’s no travel)
“2020 may be a year of imaginary travel across Zoom backgrounds, but the science is still happening and we’re not planning on missing it.”
Read our Editorial, which explains how DMM and its publisher, The Company of Biologists, have adapted the financial support they provide in response to the ongoing pandemic.
Interviews – Shohei Yoshimoto, Patricia Shaw, Jelmer Hoeksma
First authors Shohei Yoshimoto, Patricia Shaw and Jelmer Hoeksma each take us behind the scenes of their latest papers in DMM, discussing the merits of their model systems, the implications of their work and life as an early-career researcher.
Fibrodysplasia ossificans progressiva: current concepts from bench to bedside
Arun-Kumar Kaliya-Perumal, Tom J. Carney and Philip W. Ingham present a comprehensive summary of the recent literature on this debilitating condition and discuss approaches to solving this clinical puzzle.
Call for papers - The RAS Pathway: Diseases, Therapeutics and Beyond
DMM invites you to submit original research for a special issue focused on targeting the RAS pathway. The submission deadline is 1 March 2021. Find out more and showcase your breakthrough research in this special collection.
Pathological evaluation of rats carrying in-frame mutations in the dystrophin gene: a new model of Becker muscular dystrophy
In October’s Editor’s choice, Yamanouchi et al’s newly established rat model exhibits the dystrophic phenotype and abnormal dystrophin expression profile, similar to patients with Becker muscular dystrophy.